Cargando…

Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease

BACKGROUND: Despite enormous progress in elucidating the biophysics of aggregation, no cause-and-effect relationship between protein aggregation and neurodegenerative disease has been unequivocally established. Here, we derived several risk-based stochastic kinetic models that assess genotype/phenot...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugaya, Keizo, Matsubara, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468392/
https://www.ncbi.nlm.nih.gov/pubmed/22583646
http://dx.doi.org/10.1186/1750-1326-7-20
_version_ 1782245942952460288
author Sugaya, Keizo
Matsubara, Shiro
author_facet Sugaya, Keizo
Matsubara, Shiro
author_sort Sugaya, Keizo
collection PubMed
description BACKGROUND: Despite enormous progress in elucidating the biophysics of aggregation, no cause-and-effect relationship between protein aggregation and neurodegenerative disease has been unequivocally established. Here, we derived several risk-based stochastic kinetic models that assess genotype/phenotype correlations in patients with Huntington’s disease (HD) caused by the expansion of a CAG repeat. Fascinating disease-specific aspects of HD include the polyglutamine (polyQ)-length dependence of both age at symptoms onset and the propensity of the expanded polyQ protein to aggregate. In vitro, aggregation of polyQ peptides follows a simple nucleated growth polymerization pathway. Our models that reflect polyQ aggregation kinetics in a nucleated growth polymerization divided aggregate process into the length-dependent nucleation and the nucleation-dependent elongation. In contrast to the repeat-length dependent variability of age at onset, recent studies have shown that the extent of expansion has only a subtle effect on the rate of disease progression, suggesting possible differences in the mechanisms underlying the neurodegenerative process. RESULTS: Using polyQ-length as an index, these procedures enabled us for the first time to establish a quantitative connection between aggregation kinetics and disease process, including onset and the rate of progression. Although the complexity of disease process in HD, the time course of striatal neurodegeneration can be precisely predicted by the mathematical model in which neurodegeneration occurs by different mechanisms for the initiation and progression of disease processes. Nucleation is sufficient to initiate neuronal loss as a series of random events in time. The stochastic appearance of nucleation in a cell population acts as the constant risk of neuronal cell damage over time, while elongation reduces the risk by nucleation in proportion to the increased extent of the aggregates during disease progression. CONCLUSIONS: Our findings suggest that nucleation is a critical step in gaining toxic effects to the cell, and provide a new insight into the relationship between polyQ aggregation and neurodegenerative process in HD.
format Online
Article
Text
id pubmed-3468392
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34683922012-10-18 Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease Sugaya, Keizo Matsubara, Shiro Mol Neurodegener Research Article BACKGROUND: Despite enormous progress in elucidating the biophysics of aggregation, no cause-and-effect relationship between protein aggregation and neurodegenerative disease has been unequivocally established. Here, we derived several risk-based stochastic kinetic models that assess genotype/phenotype correlations in patients with Huntington’s disease (HD) caused by the expansion of a CAG repeat. Fascinating disease-specific aspects of HD include the polyglutamine (polyQ)-length dependence of both age at symptoms onset and the propensity of the expanded polyQ protein to aggregate. In vitro, aggregation of polyQ peptides follows a simple nucleated growth polymerization pathway. Our models that reflect polyQ aggregation kinetics in a nucleated growth polymerization divided aggregate process into the length-dependent nucleation and the nucleation-dependent elongation. In contrast to the repeat-length dependent variability of age at onset, recent studies have shown that the extent of expansion has only a subtle effect on the rate of disease progression, suggesting possible differences in the mechanisms underlying the neurodegenerative process. RESULTS: Using polyQ-length as an index, these procedures enabled us for the first time to establish a quantitative connection between aggregation kinetics and disease process, including onset and the rate of progression. Although the complexity of disease process in HD, the time course of striatal neurodegeneration can be precisely predicted by the mathematical model in which neurodegeneration occurs by different mechanisms for the initiation and progression of disease processes. Nucleation is sufficient to initiate neuronal loss as a series of random events in time. The stochastic appearance of nucleation in a cell population acts as the constant risk of neuronal cell damage over time, while elongation reduces the risk by nucleation in proportion to the increased extent of the aggregates during disease progression. CONCLUSIONS: Our findings suggest that nucleation is a critical step in gaining toxic effects to the cell, and provide a new insight into the relationship between polyQ aggregation and neurodegenerative process in HD. BioMed Central 2012-05-14 /pmc/articles/PMC3468392/ /pubmed/22583646 http://dx.doi.org/10.1186/1750-1326-7-20 Text en Copyright ©2012 Sugaya and Matsubara; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sugaya, Keizo
Matsubara, Shiro
Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease
title Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease
title_full Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease
title_fullStr Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease
title_full_unstemmed Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease
title_short Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntington’s disease
title_sort quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with huntington’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468392/
https://www.ncbi.nlm.nih.gov/pubmed/22583646
http://dx.doi.org/10.1186/1750-1326-7-20
work_keys_str_mv AT sugayakeizo quantitativeconnectionbetweenpolyglutamineaggregationkineticsandneurodegenerativeprocessinpatientswithhuntingtonsdisease
AT matsubarashiro quantitativeconnectionbetweenpolyglutamineaggregationkineticsandneurodegenerativeprocessinpatientswithhuntingtonsdisease